Medical technology company Teleflex (NYSE: TFX) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.3% year on year to $780.9 million. Its non-GAAP profit of $3.73 per share was 10.8% above analysts’ consensus estimates.

Is now the time to buy TFX? Find out in our full research report (it’s free).

StockStory’s Take

Teleflex’s second quarter results were marked by positive market reaction, driven largely by operational outperformance in its Interventional segment and effective margin management. Management attributed the quarter’s success to strong growth in intra-aortic balloon pumps, double-digit gains from OnControl and complex catheters, and ongoing efforts to offset cost headwinds in raw materials and logistics. CEO Liam Kelly highlighted the importance of these product categories, stating, “The upside in Interventional actually was delivered by OnControl and complex catheters.” Additionally, sequential improvement in China and progress in addressing tariff exposure contributed to the company’s results.

Looking ahead, Teleflex’s updated guidance is underpinned by the integration of the recently acquired Vascular Intervention business and strategies to mitigate tariff risks. Management emphasized that the addition of new vascular devices will create opportunities for revenue synergies by leveraging broader channel access and sales force integration globally. CFO John Deren cautioned that while tariff impacts have been reduced for 2025, the situation remains dynamic, noting, “We continue to actively explore strategies to mitigate our exposure to tariffs in 2025.” The company also pointed to proposed CMS reimbursement changes as a potential catalyst for the Urology segment.

Key Insights from Management’s Remarks

Management pointed to robust Interventional segment performance, successful cost control, and the closing of a major acquisition as key drivers shaping Q2 results and informing the company’s updated outlook.

• Interventional segment momentum: Strong double-digit growth in intra-aortic balloon pumps, OnControl, and complex catheters led the Interventional business, with management expecting high single to low double-digit growth for the segment through 2025.
• Geographic performance mixed: The Americas delivered modest growth, while EMEA saw weaker results due to softness in Anesthesia and challenging military order comparisons. In Asia, solid gains in India, Japan, and Southeast Asia were partially offset by ongoing procurement pressures in China, though sequential improvement was noted.
• Tariff mitigation progress: Teleflex reduced its projected 2025 tariff impact from $55 million to $29 million via USMCA-compliant product strategies and operational enhancements, with further mitigation efforts underway.
• BIOTRONIK Vascular Intervention acquisition: The company completed the acquisition, adding a suite of stents, drug-coated balloons, and other vascular devices. Management sees significant synergy potential through combined product portfolios and expanded channel access, especially in the Americas and EMEA.
• Urology segment and CMS proposal: While UroLift remains under pressure, management sees the proposed CMS reimbursement rules as a positive development that could restore growth potential in the office setting if enacted.

Drivers of Future Performance

Teleflex’s near-term outlook centers on integrating its new vascular assets, navigating tariff risks, and leveraging reimbursement changes to drive earnings and margin expansion.

• BIOTRONIK integration and revenue synergies: Management expects the newly acquired Vascular Intervention business to deliver mid-single-digit organic growth in the second half of 2025, with opportunities for cross-selling through expanded sales coverage. Synergy gains are anticipated as the combined portfolio strengthens Teleflex’s access to the cath lab and niche markets globally.
• Tariff exposure and pricing strategies: While tariff headwinds for 2025 are lower than initially forecast, management is actively pursuing further mitigation, including increasing USMCA-compliant products and planned price increases as contracts renew. CFO John Deren noted that substantial additional pricing benefits are likely to materialize in 2026 rather than 2025.
• Reimbursement and Urology recovery: The proposed CMS reimbursement uplift for UroLift and Barrigel could meaningfully improve profitability and utilization in the Urology segment. Management is positioning its commercial teams to capitalize on a potential shift of procedures to lower-cost office settings, supporting segment recovery in 2026 and beyond.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace and effectiveness of BIOTRONIK Vascular Intervention’s integration and its impact on Interventional segment growth; (2) additional progress on tariff mitigation and the realization of planned price increases; and (3) regulatory developments around CMS reimbursement rules for Urology. Execution on these fronts will be critical for sustaining revenue momentum and margin expansion.

Teleflex currently trades at $119.64, up from $113.93 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.